---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-019164"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2022-10-03T23:59:59+00:00"
generated_at: "2026-06-23T05:59:36.884877+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Crinetics appoints Dana Pizzuti, M.D. as Chief Development Officer effective Sept 30, 2022

## Summary
- Dr. Pizzuti appointed CDO effective Sept 30, 2022; annual base salary $525,000 and target annual bonus of 40% of base.
- She has over 30 years pharma experience, including leading regulatory at Gilead and Ascendis; helped secure marketing approvals for 15 drugs.
- Expected equity grants: stock option for 230,000 shares (25% vest Sept 30, 2023, then 36 monthly) and 12,500 RSUs (vest March 30, 2023).
- Signing bonus of $95,000 and relocation assistance; severance includes 9-12 months base salary depending on termination scenario.
- Her appointment supports upcoming Phase 3 topline data for paltusotine in acromegaly and preparation of marketing authorization applications.

## SEC filing metadata
- accession: 0000950170-22-019164
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2022-10-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017022019164/0000950170-22-019164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017022019164/crnx-20221003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-019164
- JSON: https://secwatch.observer/filing/0000950170-22-019164.json
- Plain text: https://secwatch.observer/filing/0000950170-22-019164.txt

## Key facts
- Executive change
  Dana Pizzuti was appointed as Chief Development Officer at Crinetics Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Development Officer
  source text: On October 3, 2022, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Dana Pizzuti, M.D. as the Company’s Chief Development Officer, which was effective as of September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017022019164/0000950170-22-019164-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.